1. Home
  2. ABCL vs CCAP Comparison

ABCL vs CCAP Comparison

Compare ABCL & CCAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ABCL
  • CCAP
  • Stock Information
  • Founded
  • ABCL 2012
  • CCAP 2015
  • Country
  • ABCL Canada
  • CCAP United States
  • Employees
  • ABCL N/A
  • CCAP N/A
  • Industry
  • ABCL Biotechnology: Pharmaceutical Preparations
  • CCAP Finance: Consumer Services
  • Sector
  • ABCL Health Care
  • CCAP Finance
  • Exchange
  • ABCL Nasdaq
  • CCAP Nasdaq
  • Market Cap
  • ABCL 895.0M
  • CCAP 724.9M
  • IPO Year
  • ABCL 2020
  • CCAP N/A
  • Fundamental
  • Price
  • ABCL $2.68
  • CCAP $19.45
  • Analyst Decision
  • ABCL Buy
  • CCAP Buy
  • Analyst Count
  • ABCL 3
  • CCAP 6
  • Target Price
  • ABCL $8.50
  • CCAP $19.17
  • AVG Volume (30 Days)
  • ABCL 2.4M
  • CCAP 95.4K
  • Earning Date
  • ABCL 11-04-2024
  • CCAP 11-12-2024
  • Dividend Yield
  • ABCL N/A
  • CCAP 10.49%
  • EPS Growth
  • ABCL N/A
  • CCAP 57.74
  • EPS
  • ABCL N/A
  • CCAP 2.55
  • Revenue
  • ABCL $32,962,000.00
  • CCAP $200,903,000.00
  • Revenue This Year
  • ABCL N/A
  • CCAP $9.80
  • Revenue Next Year
  • ABCL $36.56
  • CCAP N/A
  • P/E Ratio
  • ABCL N/A
  • CCAP $7.63
  • Revenue Growth
  • ABCL N/A
  • CCAP 19.05
  • 52 Week Low
  • ABCL $2.34
  • CCAP $15.91
  • 52 Week High
  • ABCL $6.06
  • CCAP $20.03
  • Technical
  • Relative Strength Index (RSI)
  • ABCL 44.26
  • CCAP 61.25
  • Support Level
  • ABCL $2.76
  • CCAP $19.54
  • Resistance Level
  • ABCL $3.05
  • CCAP $20.03
  • Average True Range (ATR)
  • ABCL 0.16
  • CCAP 0.20
  • MACD
  • ABCL -0.03
  • CCAP -0.02
  • Stochastic Oscillator
  • ABCL 0.00
  • CCAP 63.16

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

About CCAP Crescent Capital BDC Inc. Common stock

Crescent Capital BDC Inc is a business development company structured as an externally managed, closed-end, non-diversified management investment company. The company's primary investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation through debt and related equity investments. It will seek to achieve its investment objectives by investing in secured debt (including senior secured, unitranche, and second lien debt) and unsecured debt (including senior unsecured, mezzanine, and subordinated debt), as well as related equity securities of private U.S. middle-market companies.

Share on Social Networks: